Loading organizations...
Loading organizations...
Solazyme has raised $119.0M across 4 funding rounds.
Solazyme has raised $119.0M in total across 4 funding rounds.
Solazyme has raised $119.0M in total across 4 funding rounds.
Solazyme's investors include Waverley Capital, 1955 Capital.
# Solazyme: A Biotechnology Pioneer in Algae-Based Products
Solazyme was a biotechnology company that engineered microalgae to produce sustainable oils and ingredients for food, personal care, and industrial applications.[1] Founded in 2003 by Jonathan S. Wolfson and Harrison Dillon, the company developed proprietary fermentation technology to grow microalgae in controlled environments and convert plant-based sugars into high-value, customized oils.[1][3] Rather than competing in commodity markets, Solazyme positioned itself as a specialty ingredient supplier, partnering with major brands including Hormel Food Corporation, Utz Quality Foods, and Unilever to deliver algae-derived products ranging from cooking oils to cosmetics.[1][2] The company pivoted from its original focus on biofuels to food and nutrition in 2016 when it rebranded as TerraVia Holdings, reflecting market realities and investor priorities.[1][2] However, the company ultimately filed for bankruptcy in 2017, despite achieving notable commercial successes and industry recognition.[1]
Solazyme was founded on March 31, 2003, by Jonathan S. Wolfson and Harrison Dillon, two Emory University alumni who started the company in a garage in Palo Alto with an ambitious mission: to use microalgae as a renewable source of energy and transportation fuels.[1] The founders were motivated by a desire to create something transformative rather than work within large organizations, as Dillon reflected: "Neither of us wanted to go work for some giant organization where we were a tiny cog in a huge wheel."[1]
Early development proved pivotal. Between 2004 and 2005, the company developed its core algal molecular biology platform and identified microalgae-based oil production as its primary focus.[1] Critically, within approximately 18 months of founding, Wolfson and the team concluded that traditional open-pond and photobioreactor approaches using direct sunlight would not achieve commercial viability at scale or cost.[3] This realization led to their breakthrough innovation: growing microalgae in the dark inside large stainless-steel fermentation containers, a proprietary process that dramatically improved efficiency.[1]
The company went public in 2011, raising $198 million on promises of algal oil products for fuels and chemicals markets.[2] By the mid-2010s, Solazyme had achieved meaningful commercial traction, including a partnership with agribusiness giant Bunge to operate a production facility in Brazil, and had commercialized consumer brands like AlgalVia food ingredients and Algenist premium skincare products.[2]
Solazyme emerged during a period of significant investment in biobased industrial companies and renewable alternatives to petroleum-derived products. The company rode the wave of early-2010s enthusiasm for sustainable biotechnology, positioning itself at the intersection of climate concerns, industrial chemistry, and food innovation.[2] However, Solazyme's trajectory also reflects the broader challenges facing biofuels and biobased chemicals: while the technology was genuinely innovative, the economics of competing against cheap crude oil and established supply chains proved formidable.[2]
The company's strategic pivot from fuels to food and personal care in 2016 demonstrated market-driven adaptation.[1][2] Food ingredients and cosmetics offered higher margins and faster commercialization paths than industrial biofuels, where Solazyme faced competition from established players and commodity pricing pressures. This shift attracted food industry investors, including the founders of Zico Coconut Water, who provided $28 million in financing.[2]
Solazyme's story is one of genuine technological innovation constrained by market timing and capital efficiency. The company developed a genuinely differentiated platform for designing custom oils—a capability with applications across food, cosmetics, and industrial sectors. Its partnerships with major brands and industry awards demonstrated real commercial validation.
However, the 2017 bankruptcy revealed the tension between technological prowess and business model sustainability. Despite pivoting to higher-margin food and personal care markets, the company struggled to achieve profitability at the scale required to justify its public market valuation and burn rate.[2] The experience mirrors that of peer biobased firms like Gevo and KiOR, suggesting that even breakthrough biotechnology requires not just innovation but also favorable unit economics and market timing.[2]
For the broader ecosystem, Solazyme's rise and fall underscored that sustainable alternatives require either commodity-scale economics or premium market positioning—and that the transition between the two is perilous. The company's technical achievements in algae fermentation and oil tailoring remain valuable intellectual property, but its inability to sustain operations highlights the capital intensity and execution challenges inherent in scaling biotechnology ventures.
Solazyme has raised $119.0M across 4 funding rounds. Most recently, it raised $52.0M Series D in August 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2010 | $52.0M Series D | Waverley Capital | |
| Jun 1, 2009 | $12.0M Series D | 1955 Capital, Waverley Capital | |
| Aug 1, 2008 | $45.0M Series C | 1955 Capital, Waverley Capital | |
| Mar 1, 2007 | $10.0M Series B | Waverley Capital |